This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Enzo Life Sciences
other brands :
Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis
product type :
protein
product name :
Src (human), (recombinant) (GST-tag)
catalog :
BML-SE357-0005
quantity :
5 µg
product information
Product ID :
BML-SE357
Catalog Number :
BML-SE357-0005
Product Name :
Src (human), (recombinant) (GST-tag)
Product Type :
Protein
Size :
5 µg
Background :
Src, a non-receptor type tyrosine kinase, is a proto-oncogene that plays key roles in cell morphology, motility, proliferation, and survival. Src is overexpressed and activated in a large number of human cancers. Oncogenic forms of Src alter cell structure and affect thin filaments and adhesion networks that control cell migration. Src also influences the RhoA-ROCK pathway that controls actin polymerization, the STAT family of transcription factors which are involved in tumorigenesis and the Cbl ubiquitin ligase that controls Src protein levels.
ALTnames :
pp60src
Purity :
≥95% (SDS-PAGE)
Buffer :
Liquid. In 50mM TRIS-HCl, pH 7.5, containing 150mM sodium chloride, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.
Uses :
Useful for kinetic and functional studies, phosphorylation of target substrates, drug screening.
Storage :
-80°C
company information
Enzo Life Sciences
5777 Hines Drive
Ann Arbor, MI 48108
Ann Arbor, MI 48108
info-us@enzolifesciences.
https://www.enzolifesciences.com1-800-942-0430
headquarters: USA
Enzo Life Sciences, incorporating ALEXIS® Biochemicals and BIOMOL® International, offers a comprehensive panel of innovative life science reagents. Antibodies, enzymes, proteins, small molecule inhibitors, product libraries, and assay kits are available for research in Cancer, Cell Death, Epigenetics, Genomics, Immunology, Neuroscience, Signal Transduction, and Ubiquitin & Proteasomes, Enabling Discovery in Life Science(tm). Visit www.enzolifesciences.com.
questions and comments